• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡非尼酮的饮食摄入可改善博来霉素诱导的仓鼠肺纤维化。

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.

作者信息

Iyer S N, Wild J S, Schiedt M J, Hyde D M, Margolin S B, Giri S N

机构信息

Department of Molecular Biosciences, University of California-Davis, USA.

出版信息

J Lab Clin Med. 1995 Jun;125(6):779-85.

PMID:7539478
Abstract

There are no clinically efficacious drugs available for preventing the development of pulmonary fibrosis (PF). In the present study, we tested the antifibrotic potential of pirfenidone (PD) in the bleomycin (BL) hamster model of PF. Hamsters were intratracheally instilled with isotonic saline solution or BL (7.5 U/kg/5 ml). The animals were fed control diet containing 0.5% PD or the same diet without the drug 2 days before and throughout the study. The four groups were as follows: saline-instilled and fed the control diet (SCD); saline-instilled and fed the same diet containing PD (SPD); BL-instilled and fed the control diet (BCD); and BL-instilled and fed the same diet containing PD (BPD). The animals were killed at 21 days after intratracheal instillation and their lungs processed for various assays. The lung hydroxyproline levels, an index of PF, in SCD, SPD, BCD, and BPD groups were 949, 970, 1759, and 990 micrograms/lung, respectively. The SOD activity and malondialdehyde equivalent levels in the corresponding groups were 443, 524, 612, and 499 units/lung and 56, 49, 108, and 63 nmol/lung, respectively. The lung prolyl hydroxylase activities in the SPD, BCD, and BPD groups were 87%, 147%, and 93% of the control (SCD) group (4.2 x 10(4) dpm/lung/30 minutes), respectively. The lung myeloperoxidase activities were 97%, 236%, and 159% of the control group (0.73 units/lung), respectively. BL alone caused significant increases in all the biochemical markers of lung toxicity, and dietary intake of PD minimized the BL toxicity as reflected by significant decreases in all the above markers.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

目前尚无临床有效的药物可用于预防肺纤维化(PF)的发生。在本研究中,我们在博来霉素(BL)诱导的PF仓鼠模型中测试了吡非尼酮(PD)的抗纤维化潜力。仓鼠经气管内注入等渗盐溶液或BL(7.5 U/kg/5 ml)。在研究前2天及整个研究过程中,给动物喂食含0.5% PD的对照饮食或不含该药物的相同饮食。四组如下:注入盐水并喂食对照饮食(SCD);注入盐水并喂食含PD的相同饮食(SPD);注入BL并喂食对照饮食(BCD);注入BL并喂食含PD的相同饮食(BPD)。气管内注入后21天处死动物,取肺进行各种检测。SCD、SPD、BCD和BPD组的肺羟脯氨酸水平(PF的一个指标)分别为949、970、1759和990微克/肺。相应组的超氧化物歧化酶(SOD)活性和丙二醛当量水平分别为443、524、612和499单位/肺以及56、49、108和63纳摩尔/肺。SPD、BCD和BPD组的肺脯氨酰羟化酶活性分别为对照组(SCD)(4.2×10⁴ dpm/肺/30分钟)的87%、147%和93%。肺髓过氧化物酶活性分别为对照组(0.73单位/肺)的97%、236%和159%。单独使用BL导致肺毒性的所有生化指标显著升高,而饮食中摄入PD可使BL毒性降至最低,上述所有指标均显著降低。(摘要截断于250字)

相似文献

1
Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.吡非尼酮的饮食摄入可改善博来霉素诱导的仓鼠肺纤维化。
J Lab Clin Med. 1995 Jun;125(6):779-85.
2
Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model.在三剂量博来霉素-仓鼠模型中,第二剂后通过饮食给予吡非尼酮可改善肺纤维化。
Exp Lung Res. 1998 Jan-Feb;24(1):119-32. doi: 10.3109/01902149809046058.
3
Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.吡非尼酮对博莱霉素诱导的肺纤维化仓鼠模型中前胶原基因转录水平表达的影响。
J Pharmacol Exp Ther. 1999 Apr;289(1):211-8.
4
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.吡非尼酮对博莱霉素诱导的肺纤维化仓鼠模型转录水平转化生长因子-β基因表达的影响。
J Pharmacol Exp Ther. 1999 Oct;291(1):367-73.
5
Procollagen gene expression is down-regulated by taurine and niacin at the transcriptional level in the bleomycin hamster model of lung fibrosis.在博来霉素诱导的肺纤维化仓鼠模型中,前胶原基因表达在转录水平受到牛磺酸和烟酸的下调。
J Pharmacol Exp Ther. 1996 May;277(2):1152-7.
6
Effects of delayed treatment with transforming growth factor-beta soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters.在仓鼠三剂量博来霉素诱导的肺纤维化模型中,转化生长因子-β可溶性受体延迟治疗的效果。
Exp Lung Res. 2002 Sep;28(6):405-17. doi: 10.1080/01902140290096700.
7
Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis.核心蛋白聚糖在博来霉素诱导的肺纤维化仓鼠模型中的抗纤维化作用。
Biochem Pharmacol. 1997 Dec 1;54(11):1205-16. doi: 10.1016/s0006-2952(97)00343-2.
8
Effects of niacin on bleomycin-induced increases in myeloperoxidase, prolyl hydroxylase, and superoxide dismutase activities and collagen accumulation in the lungs of hamsters.烟酸对博来霉素诱导的仓鼠肺中髓过氧化物酶、脯氨酰羟化酶和超氧化物歧化酶活性增加以及胶原蛋白积累的影响。
J Biochem Toxicol. 1992 Winter;7(4):229-39. doi: 10.1002/jbt.2570070406.
9
Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin.通过牛磺酸和烟酸联合治疗减轻博来霉素诱导的仓鼠肺血管通透性增加、炎症细胞浸润和纤维化病变。
Lab Invest. 1992 Aug;67(2):234-42.
10
Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters.
Proc Soc Exp Biol Med. 1997 Dec;216(3):392-7. doi: 10.3181/00379727-216-44187.

引用本文的文献

1
Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data.吡非尼酮在皮肤纤维化和瘢痕形成中的作用:从实验室研究到临床数据
Med Sci (Basel). 2025 Aug 20;13(3):148. doi: 10.3390/medsci13030148.
2
Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis.阻断肿瘤坏死因子超家族成员14和15的联合疗法可逆转肺纤维化。
J Immunol. 2025 Apr 1;214(4):808-817. doi: 10.1093/jimmun/vkaf002.
3
The allure of targets for novel drugs.新型药物靶点的吸引力。
RSC Med Chem. 2023 Dec 13;15(2):472-484. doi: 10.1039/d3md00621b. eCollection 2024 Feb 21.
4
A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.药物治疗特发性肺纤维化的安全性和有效性综合比较:基于随机对照试验的网状Meta分析
BMC Pulm Med. 2024 Jan 27;24(1):58. doi: 10.1186/s12890-024-02861-w.
5
Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension.特发性肺纤维化:探讨当前和未来的治疗进展以及 Sotatercept 在肺动脉高压管理中的作用。
Immun Inflamm Dis. 2023 Nov;11(11):e1079. doi: 10.1002/iid3.1079.
6
Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin.吡非尼酮对博来霉素诱导的大鼠肺纤维化的保护作用
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023036. doi: 10.36141/svdld.v40i3.13847.
7
Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone.抑制 MRTF 激活作为吡非尼酮的一种可行的抗纤维化机制。
Eur Respir J. 2023 Apr 27;61(4). doi: 10.1183/13993003.00604-2022. Print 2023 Apr.
8
Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial.吡非尼酮预防局部晚期食管鳞癌患者放射性肺损伤的随机对照试验方案。
BMJ Open. 2022 Oct 27;12(10):e060619. doi: 10.1136/bmjopen-2021-060619.
9
TGF-β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation.转化生长因子-β1通过促进纤维化和炎症反应介导继发性淋巴水肿的病理变化。
Clin Transl Med. 2022 Jun;12(6):e758. doi: 10.1002/ctm2.758.
10
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond.吡非尼酮用于特发性肺纤维化及其他病症
Card Fail Rev. 2022 Apr 14;8:e12. doi: 10.15420/cfr.2021.30. eCollection 2022 Jan.